These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12697369)

  • 1. Month 3 and month 6 measurements of bone mineral density predict the annual outcome in postmenopausal women with osteoporosis in whom alendronate was added to long-term HRT.
    Pines A; Eckstein N; Kopernik G; Ayalon D; Comaneshter D; Frenkel Y
    Maturitas; 2003 Apr; 44(4):287-92. PubMed ID: 12697369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
    N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
    Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P; Clemmesen B; Christiansen C
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
    Hejdova M; Palicka V; Kucera Z; Vlcek J
    Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
    N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
    Tseng LN; Sheu WH; Ho ES; Lan HH; Hu CC; Kao CH
    Metabolism; 2006 Jun; 55(6):741-7. PubMed ID: 16713432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
    Duan Y; Tabensky A; DeLuca V; Seeman E
    Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
    Insua A; Negri A; Zanchetta JR
    Medicina (B Aires); 1995; 55(5 Pt 1):408-14. PubMed ID: 8728770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of bone loss in peri- and postmenopausal women: a 4 year, prospective, population-based study.
    Young R; May H; Murphy S; Grey C; Compston JE
    Clin Sci (Lond); 1996 Sep; 91(3):307-12. PubMed ID: 8869413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of nutritional calcium and HRT in prevention of postmenopausal bone loss: a prospective study.
    Sirola J; Kröger H; Sandini L; Tuppurainen M; Jurvelin JS; Saarikoski S; Honkanen R
    Calcif Tissue Int; 2003 Jun; 72(6):659-65. PubMed ID: 14562993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
    Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density.
    Thompson JM; Modin GW; Arnaud CD; Lane NE
    Calcif Tissue Int; 1997 Nov; 61(5):377-81. PubMed ID: 9351878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.